I agree with you on this
if…. The material growth policy from CBI only applies during remediation period then come March 2022 the company will have $160m+ at hand and we’ll be on a run rate circa $270-$300m turnover
were a much better business yoy with vaccines, 18 months of new programs under the hood (circa 200) + hopefully an uninterrupted Xmas trading season to boost full year profitability margins
time will tell I guess
ps good to see some old friends back in the thread!
Ann: Investor Briefing, page-92
Add EML (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.0¢ |
Change
-0.005(0.75%) |
Mkt cap ! $249.6M | |||
| Open | High | Low | Value | Volume |
| 67.5¢ | 68.0¢ | 66.0¢ | $400.7K | 600.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 164252 | 66.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 67.0¢ | 95852 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| EML (ASX) Chart |